Don´t give up on mitochondria as a target for the treatment of diabetes and its complications  

作　　者：Christian Cortés-Rojo Manuel Alejandro Vargas-Vargas 

机构地区：[1]Instituto de Investigaciones Químico-Biológicas,Universidad Michoacana de San Nicolás de Hidalgo,Morelia 58030,Michoacán,Mexico

出　　处：《World Journal of Diabetes》2024年第10期2015-2021,共7页世界糖尿病杂志（英文）

基　　金：Supported by Instituto de Ciencia,Tecnología e Innovación-Gobierno del Estado de Michoacán,México,No.ICTI-PICIR23-063;Programa Proyectos de Investigación Financiados 2024,Coordinación de Investigación Científica,Universidad Michoacana de San Nicolás de Hidalgo,México.

摘　　要：In this editorial,we discuss an article by Wang et al,focusing on the role of mitochondria in peripheral insulin resistance and insulin secretion.Despite numerous in vitro and pre-clinical studies supporting the involvement of mitochondrial dysfunction and oxidative stress in the pathogenesis of diabetes and its complications,efforts to target mitochondria for glycemic control in diabetes using mitochondria-targeted antioxidants have produced inconsistent results.The intricate functionality of mitochondria is summarized to underscore the challenges it poses as a therapeutic target.While mitochondria-targeted antioxidants have demonstrated improvement in mitochondrial function and oxidative stress in pre-clinical diabetes models,the results regarding glycemic control have been mixed,and no studies have evaluated their hypoglycemic effects in diabetic patients.Nonetheless,pre-clinical trials have shown promising outcomes in ameliorating diabetes-related complications.Here,we review some reasons why mitochondria-targeted antioxidants may not function effectively in the context of mitochondrial dysfunction.We also highlight several alternative approaches under development that may enhance the targeting of mitochondria for diabetes treatment.

关 键 词：Diabetes mellitus Insulin resistance MITOCHONDRION Mitochondrial dysfunction MITOQ MitoTEMPO SKQ Elamipretide Mitochondria transplantation Glycemic control 

分 类 号：R587.1[医药卫生—内分泌]